China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received a Class 1 recommendation from the Chinese Society of Clinical Oncology (CSCO) for the treatment of relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) in its 2025 guidelines. This endorsement highlights the drug’s significant impact on patient outcomes in this challenging disease setting.
Golidocitinib’s Market Approval and Clinical Performance
Golidocitinib was approved for marketing in China in June of the previous year, marking it as the first and only Janus kinase 1 (JAK1) selective inhibitor globally for patients with r/r PTCL. The recommendation from the CSCO guidelines is supported by data from the JACKPOT8 study, which demonstrated a median overall survival (mOS) of 24.3 months with golidocitinib monotherapy for r/r PTCL. This result, achieved with follow-up until February 2024, represents a breakthrough as the longest mOS for a monotherapy in this indication.-Fineline Info & Tech
